133 related articles for article (PubMed ID: 38145825)
1. TOX3 deficiency mitigates hyperglycemia by suppressing hepatic gluconeogenesis through FoxO1.
Liu C; Zheng Y; Hu S; Liang X; Li Y; Yu Z; Liu Y; Bian Y; Man Y; Zhao S; Liu X; Liu H; Huang T; Ma J; Chen ZJ; Zhao H; Zhang Y
Metabolism; 2024 Mar; 152():155766. PubMed ID: 38145825
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal Regulation of Hepatic TGF-β1 and Foxo1 Controls Gluconeogenesis and Energy Expenditure.
Pan Q; Ai W; Chen Y; Kim DM; Shen Z; Yang W; Jiang W; Sun Y; Safe S; Guo S
Diabetes; 2023 Sep; 72(9):1193-1206. PubMed ID: 37343276
[TBL] [Abstract][Full Text] [Related]
3. An insulin-independent mechanism for transcriptional regulation of Foxo1 in type 2 diabetic mice.
Ge W; Zhao Y; Yang Y; Ding Z; Xu X; Weng D; Wang S; Cheng R; Zhang J
J Biol Chem; 2021 Jul; 297(1):100846. PubMed ID: 34058194
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA H19 inhibition promotes hyperglycemia in mice by upregulating hepatic FoxO1 levels and promoting gluconeogenesis.
Goyal N; Tiwary S; Kesharwani D; Datta M
J Mol Med (Berl); 2019 Jan; 97(1):115-126. PubMed ID: 30465059
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 regulates hepatic glucose metabolism by targeting FOXO1.
Luo A; Yan H; Liang J; Du C; Zhao X; Sun L; Chen Y
Gene; 2017 Sep; 627():194-201. PubMed ID: 28627440
[TBL] [Abstract][Full Text] [Related]
6. Micro-RNA-27a/b negatively regulates hepatic gluconeogenesis by targeting FOXO1.
Wang S; Ai H; Liu L; Zhang X; Gao F; Zheng L; Yi J; Sun L; Yu C; Zhao H; Li Y
Am J Physiol Endocrinol Metab; 2019 Nov; 317(5):E911-E924. PubMed ID: 31526292
[TBL] [Abstract][Full Text] [Related]
7. Estrogen Improves Insulin Sensitivity and Suppresses Gluconeogenesis via the Transcription Factor Foxo1.
Yan H; Yang W; Zhou F; Li X; Pan Q; Shen Z; Han G; Newell-Fugate A; Tian Y; Majeti R; Liu W; Xu Y; Wu C; Allred K; Allred C; Sun Y; Guo S
Diabetes; 2019 Feb; 68(2):291-304. PubMed ID: 30487265
[TBL] [Abstract][Full Text] [Related]
8. DDB1-Mediated CRY1 Degradation Promotes FOXO1-Driven Gluconeogenesis in Liver.
Tong X; Zhang D; Charney N; Jin E; VanDommelen K; Stamper K; Gupta N; Saldate J; Yin L
Diabetes; 2017 Oct; 66(10):2571-2582. PubMed ID: 28790135
[TBL] [Abstract][Full Text] [Related]
9. Hepatic p38α MAPK controls gluconeogenesis via FOXO1 phosphorylation at S273 during glucagon signalling in mice.
Yang W; Liao W; Li X; Ai W; Pan Q; Shen Z; Jiang W; Guo S
Diabetologia; 2023 Jul; 66(7):1322-1339. PubMed ID: 37202506
[TBL] [Abstract][Full Text] [Related]
10. Repression of Transcriptional Activity of Forkhead Box O1 by Histone Deacetylase Inhibitors Ameliorates Hyperglycemia in Type 2 Diabetic Rats.
Cho HM; Seok YM; Lee HA; Song M; Kim I
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424007
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-721 regulates gluconeogenesis via KDM2A-mediated epigenetic modulation in diet-induced insulin resistance in C57BL/6J mice.
Kabeer SW; Sharma S; Sriramdasu S; Tikoo K
Biol Res; 2024 May; 57(1):27. PubMed ID: 38745315
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-451 Negatively Regulates Hepatic Glucose Production and Glucose Homeostasis by Targeting Glycerol Kinase-Mediated Gluconeogenesis.
Zhuo S; Yang M; Zhao Y; Chen X; Zhang F; Li N; Yao P; Zhu T; Mei H; Wang S; Li Y; Chen S; Le Y
Diabetes; 2016 Nov; 65(11):3276-3288. PubMed ID: 27495223
[TBL] [Abstract][Full Text] [Related]
13. GdCl3 reduces hyperglycaemia through Akt/FoxO1-induced suppression of hepatic gluconeogenesis in Type 2 diabetic mice.
Wang Q; Wang N; Dong M; Chen F; Li Z; Chen Y
Clin Sci (Lond); 2014 Jul; 127(2):91-100. PubMed ID: 24444370
[TBL] [Abstract][Full Text] [Related]
14. MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver.
Tian F; Ying HM; Wang YY; Cheng BN; Chen J
Yonsei Med J; 2020 Sep; 61(9):780-788. PubMed ID: 32882762
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice.
Altomonte J; Richter A; Harbaran S; Suriawinata J; Nakae J; Thung SN; Meseck M; Accili D; Dong H
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E718-28. PubMed ID: 12783775
[TBL] [Abstract][Full Text] [Related]
16. TCF7L2 modulates glucose homeostasis by regulating CREB- and FoxO1-dependent transcriptional pathway in the liver.
Oh KJ; Park J; Kim SS; Oh H; Choi CS; Koo SH
PLoS Genet; 2012 Sep; 8(9):e1002986. PubMed ID: 23028378
[TBL] [Abstract][Full Text] [Related]
17. A decrease in hepatic microRNA-9 expression impairs gluconeogenesis by targeting FOXO1 in obese mice.
Yan C; Chen J; Li M; Xuan W; Su D; You H; Huang Y; Chen N; Liang X
Diabetologia; 2016 Jul; 59(7):1524-1532. PubMed ID: 27003684
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin F
Wang Y; Yan S; Xiao B; Zuo S; Zhang Q; Chen G; Yu Y; Chen D; Liu Q; Liu Y; Shen Y; Yu Y
Diabetes; 2018 Sep; 67(9):1748-1760. PubMed ID: 29773555
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice.
Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J
Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia.
Wang Y; Spolitu S; Zadroga JA; Sarecha AK; Ozcan L
Cell Rep; 2022 Aug; 40(8):111259. PubMed ID: 36001955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
